What is Stage 3A Chronic Kidney Disease?
Stage 3A chronic kidney disease (CKD) is defined as a mild to moderate decrease in kidney function with an estimated glomerular filtration rate (eGFR) of 45-59 mL/min/1.73 m² that has been present for more than 3 months. 1
Definition and Classification
Stage 3A CKD represents one subdivision of Stage 3 CKD, which has been split into two categories based on significantly different prognosis:
This subdivision is clinically important because Stage 3B patients have substantially higher risks of adverse renal and cardiovascular outcomes compared to Stage 3A patients 3, 4. The diagnosis requires that kidney abnormalities be present for at least 3 months to distinguish chronic from acute kidney injury 5.
Clinical Significance
Complications of CKD generally become prevalent when eGFR falls below 60 mL/min/1.73 m² (Stage 3 or greater). 6 At this level of kidney function, you should begin evaluating for:
- Elevated blood pressure (>140/90 mmHg)
- Volume overload
- Electrolyte abnormalities and metabolic acidosis
- Anemia (check hemoglobin and iron studies)
- Metabolic bone disease (serum calcium, phosphate, PTH, vitamin 25(OH)D) 6
Laboratory monitoring frequency for Stage 3A should occur every 6-12 months, or more frequently if symptoms develop or therapy changes 6.
Prognosis and Progression
Approximately half of patients with Stage 3 CKD will progress to Stage 4 or 5 over 10 years, though Stage 3A patients have significantly better outcomes than Stage 3B. 3 The key independent predictors of progression are:
- Macroalbuminuria (hazard ratio 3.06)
- Microscopic hematuria (hazard ratio 2.07)
- Stage 3B vs 3A (hazard ratio 2.99)
- Microalbuminuria (hazard ratio 1.99) 3
Importantly, many elderly patients with Stage 3A CKD without albuminuria may never progress and some may even improve 7. However, the vast majority of Stage 3 CKD patients die from cardiovascular causes rather than progressing to end-stage renal disease 8.
Management Approach
Primary care intervention for cardiovascular risk reduction is essential, as cardiovascular mortality exceeds the risk of progression to dialysis in Stage 3A CKD. 9, 8
Blood Pressure Management
- Target <140/90 mmHg
- Use ACE inhibitors or ARBs preferentially if albuminuria is present (UACR ≥30 mg/g) 1
Glucose Control (if diabetic)
- Consider SGLT2 inhibitors or GLP-1 receptor agonists, which have direct renal protective effects beyond glycemic control 6
- Metformin can be continued with eGFR 45-59 mL/min/1.73 m² but requires monitoring 6
Protein Intake
- Restrict to approximately 0.8 g/kg/day 1
Monitoring
- Annual screening with UACR and eGFR at minimum 1
- Laboratory evaluation every 6-12 months for complications 6
Referral Considerations
Nephrology referral is not routinely required for Stage 3A CKD if the diagnosis is clear, kidney function is stable, and the primary care provider is comfortable managing the condition. 9, 8 However, consider referral for:
- Persistent proteinuria >1 g/day (ACR ≥60 mg/mmol or PCR ≥100 mg/mmol)
- Abrupt sustained decrease in eGFR >20% after excluding reversible causes
- Inability to meet blood pressure goals
- Severe electrolyte abnormalities
- Uncertainty about diagnosis
- Intolerance to renal protective medications 9
Formal nephrology referral becomes standard when eGFR falls below 30 mL/min/1.73 m² (Stage 4). 9, 8